RxDoctor Payments Data

Radhika Kumar, MD

Ophthalmology · Cincinnati, OHNPI 1427137470

Payments from drug & device makers

$5,489in general payments, 2019–2025

Across 106 payments — averaging $51.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Haag-streit USA, Inc.$3K
  • Alcon$455
  • AbbVie$270
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$225
  • Bausch & Lomb Americas Inc.$188
  • Novartis$182
  • plus $1K from 14 others

What the payments were for

  • Consulting fees$3,00055%
  • Food & beverage$2,48945%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,489 in reported general payments places this provider in the 80th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$203,208
Medicare patients
603
Services billed
1,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj19$599,934
RestasisCyclosporine212$229,330
XiidraLifitegrast100$154,809
Cyclosporine27$20,300
Fluorometholone208$12,138
Loteprednol Etabonate97$11,312
Prednisolone Acetate353$9,355
LumiganBimatoprost15$9,221
ProlensaBromfenac Sodium22$7,303
CequaCyclosporine12$7,031
Lotemax SmLoteprednol Etabonate22$5,682
MoxifloxacinMoxifloxacin Hcl242$5,550
Bromfenac Sodium26$4,983
CombiganBrimonidine Tartrate/Timolol12$2,601
ValacyclovirValacyclovir Hcl64$2,307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$134$599,93419 claims
AbbVieRestasis, Lumigan, Combigan$270$241,152239 claims
Bausch & Lomb Americas Inc.Xiidra$188$154,809100 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa, Lotemax Sm$225$24,297141 claims
Sun Pharmaceutical Industries Inc.Cequa$176$7,03112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →